Once-weekly semaglutide reduced body mass index by a mean of 13.5% at week 68 in children ages 6 to under 12 with obesity, compared with a 2.7% increase with placebo, according to a phase 3 trial published Nov. 16 in the New England Journal of Medicine.
Here are six things to know:
- The STEP Young trial randomized 167 children 2-to-1 to semaglutide (112 children) or placebo (55 children) for 104 weeks, with both groups receiving lifestyle counseling. The primary endpoint was the percent change in BMI from baseline to week 68. The estimated difference between groups was 16.2 percentage points.
- At week 104, BMI had fallen 9.4% with semaglutide and risen 8.4% with placebo, a between-group difference of 17.8 percentage points. The trial included a seven-week washout period after treatment ended.
- At week 68, 79% of children on semaglutide had a reduction in BMI category, compared with 23% on placebo. A BMI below the threshold for obesity, the 95th percentile for age and sex, was reached by 38% of children on semaglutide and 2% on placebo.
- Adverse events occurred in 96% of children on semaglutide and 93% on placebo. Gastrointestinal events were the most common and occurred more often with semaglutide. They led one child in the semaglutide group to discontinue treatment.
- The authors wrote that childhood obesity is a chronic disease with limited effective and durable medical treatments and that data on semaglutide in young children had been lacking. Wegovy is approved for adolescents 12 and older. The study was funded by Novo Nordisk, which makes the drug.
- GLP-1 use among young children is growing quickly. Use among children ages 8 to 11 with obesity rose from 0.03% in 2019 to 9.3% in 2026, and the World Health Organization’s first youth obesity guidelines do not recommend drug treatment for children ages 0 to 9.